Cancel
Mary Beth Dorr
Vice President, Clinical Science
@
Venatorx Pharmaceuticals
lk8i.iypq@gz189151.3f8
Sign up to see email
See Linkedin
Known information
- Has a Ph.D. in Pharmaceutics with an emphasis on pharmacokinetics and drug metabolism from the University of North Carolina in Chapel Hill, N.C.
- Received a B.S. in Pharmacy from the University of the Sciences in Philadelphia.
- Completed a clinical pharmacy residency at the Veteran's Administration Hospital in Philadelphia.
- Worked as Product Development Team Leader and Clinical Lead, Infectious Diseases at Merck.
- Led the clinical development for ZINPLAVA (bezlotoxumab) at Merck.
- Led the development teams for DIFICID (fidaxomicin) and CUBICIN (daptomycin) at Merck.
- Was Senior Director, Global Medical Affairs at Wyeth.
- Served as Pandemic Preparedness Advisor at Wyeth.
- Was the development team project manager at Vicuron Pharmaceuticals for dalbavancin.
- Worked at Rhône-Poulenc Rorer as a senior research scientist responsible for clinical pharmacokinetic development for ZAGAM (sparfloxacin).
- Managed Phase 1 and 3 trials for ZAGAM and several Phase 3b trials for SYNERCID (quinupristin/dalfopristin) at Rhône-Poulenc Rorer.
- Worked at Parke-Davis designing and implementing preclinical and clinical pharmacokinetic research for several quinolone antibiotics.
- Has over 30 years of experience in drug development, primarily for anti-infective products.
About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals, founded in June 2010, focuses on developing novel anti-infectives to treat multi-drug-resistant bacterial and hard-to-treat viral infections. Their lead asset, cefepime-taniborbactam, has completed a Phase 3 study for complicated urinary tract infections and is under FDA review.
Report inaccurate information